Pichia pastoris as One of the Best Choice for Expression of Biopharmaceutical Proteins

Bioproducts such as vaccines, antibodies, antiviral peptideslike interferon-, insulin, growth hormone (GH) anderythropoietin are models of biopharmaceuticals whichare applied for therapeutic goals in modern medicine; In۲۰۱۴, the global market has been estimated ۴۴ billion $for recombinant biopharmaceutical proteins which is predictedthat extended to ۷۰ billion $ in ۲۰۱۰ (۱, ۲). In theother hand, during last decades, the mammalian cell linesand Escherichia coli expression systems are available optionsfor expressing and production of recombinant proteins;but there are serious problems such as slow growthrate replication, requiring to expensive synthetic mediaand susceptibility to viral contamination in mammaliancell lines, while bacterial expressing systems are associatedwith phage contamination, need to purification ofbacterial toxins and limited in post modification translation(PMT) process (۱-۳). Beside these problems, increasingglobally demands of biopharmaceutical proteins havebeen major reasons for developing genetic-manipulationprocess to introduction of new efficient expressing systemwhich high-yield economical (۲, ۴).